SCHEDULE: Baslake Partners Discloses 4.1% Stake in Neuphoria Therapeutics

Baslake Partners, LP, along with its investment manager Baselake Management, LLC and managing member David Paolella, has disclosed a 4.1% beneficial ownership stake in Neuphoria Therapeutics Inc.

Summary

• Baslake Partners, LP, Baselake Management, LLC, and David Paolella collectively reported beneficial ownership of 222,222 shares of Neuphoria Therapeutics Inc. common stock.
• This represents 4.1% of the issuer's outstanding common stock.
• The percentage is calculated based on 5,377,329 shares issued and outstanding as of November 13, 2025, as stated in the Issuer's 10-Q.
• The reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest.
• The shares are held by Baselake Partners, LP, with Baselake Management, LLC serving as its investment manager, and David Paolella as the managing member of the Investment Manager.
• All reporting persons share voting and dispositive power over the 222,222 shares.
• The acquisition of these securities was not for the purpose of changing or influencing control of Neuphoria Therapeutics Inc.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, indicating institutional interest in Neuphoria Therapeutics without suggesting any immediate strategic shifts or activist intentions.

Positives

• A significant institutional investor, Baselake Partners, has taken a notable stake in Neuphoria Therapeutics, potentially signaling confidence in the company's long-term prospects.
• The filing explicitly states the acquisition was not for the purpose of changing or influencing control, which can reduce concerns about potential activist investor actions.

Negatives

• The ownership stake is below the 5% threshold, meaning Baselake Partners does not have to file a Schedule 13D, which would require more detailed disclosure of intent, thus limiting insight into their strategic rationale beyond the general statement.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that institutional ownership disclosures like this Schedule 13G provide transparency into significant investor positions. While a 4.1% stake is below the 5% threshold for a Schedule 13D, it still indicates a notable investment by Baselake Partners, a Delaware-based entity, in Neuphoria Therapeutics, a company in the biotechnology or pharmaceutical sector (implied by "Therapeutics"). Such investments can sometimes precede further accumulation or signal a broader trend of institutional interest in the sector.

Comparison to Industry Standards

• StockSavvy.ai observes that a 4.1% stake is a substantial position for an institutional investor, though it falls short of the 5% threshold that would trigger a more detailed Schedule 13D filing, which often indicates a more active or potentially activist investment strategy.
• For comparison, other biotech companies often see institutional investors accumulate stakes ranging from 5% to 15% before engaging in more direct dialogue with management or seeking board representation. This 4.1% stake suggests a passive investment for now, consistent with a Schedule 13G filing.

Stakeholder Impact

• Shareholders: The disclosure of a new institutional investor taking a significant stake could be viewed positively, potentially increasing investor confidence and liquidity.
• Management: Management may view this as a vote of confidence, though they will likely monitor Baselake Partners' future actions.

Key Dates

Recommendation

While the disclosure of a 4.1% stake by Baselake Partners is a positive signal of institutional interest, it is a passive investment below the 5% threshold. This filing alone does not provide sufficient new information to warrant a "buy" or "sell" recommendation, suggesting a "hold" position is appropriate for investors to observe further developments or company performance.

Keywords

Neuphoria Therapeutics, Baslake Partners, Baslake Management, David Paolella, Schedule 13G, beneficial ownership, common stock, institutional investment, SEC filing, equity stake